<DOC>
	<DOCNO>NCT00805389</DOCNO>
	<brief_summary>The aim Observer-blind study compare different Adjuvant Systems , well-known antigen ( HBsAg ) already use GSK market vaccine Hepatitis B ( Engerix-BTM FendrixTM ) , order well understand immune response induce Adjuvant System . This Protocol Posting update follow Protocol amendment 6 , October 2009 . The section impact Eligibility Criteria</brief_summary>
	<brief_title>Study Compare Efficacy GSK Biologicals ' Adjuvants Combination With Antigen Hepatitis B Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy follow criterion study entry : Subjects investigator believe comply requirement protocol . A male female , include , 18 45 year time first vaccination . Written inform consent obtain subject . Healthy subject establish medical history , clinical examination clinical laboratory assessment enter study . If subject female , must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Exclusion criterion : The follow criterion check time study entry . If apply , subject must include study : Previous vaccination Hepatitis B . Positive antiHBs antibody , antiHBc antibody , HBsAg , HCV antibodies and/or HIV . Any previous administration specific adjuvant component . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period participation another pharmaceutical/vaccine study . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol within 30 day first dose vaccine exception influenza vaccine ( pandemic seasonal ) administer &gt; 21 day precede &gt; 21 day follow primary vaccine dose ( Doses 1 2 ) AND &gt; 7 day precede &gt; 7 day follow booster dose . Administration immunoglobulins and/or blood product within last 3 month . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History allergic disease reaction likely exacerbate component vaccine ( ) . Current serious neurologic mental disease . Any past current malignancy lymphoproliferative disorder . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic , renal functional abnormality , autoimmune disease anemia , determine physical examination laboratory screen test discretion investigator . Acute disease time enrolment . Pregnant lactate female . History chronic alcohol consumption and/or drug abuse . Other condition principal investigator judge may interfere study finding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Adjuvant Systems</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>